Lead Sponsor

Bristol-Myers Squibb

Collaborators

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

No

•Detectable HIV viremia (HIV-1 RNA level between 1,000 and 100,000 copies/mL)
•CD4 count greater than or equal to 100 cells/mm3
•Current antiretroviral therapy regimen following at least 2 previous changes for documented virologic failure
•Documented resistance tests demonstrating the presence of at least 1 mutation to each major therapeutic class of antiretroviral therapy
•No significant organ compromise

•Initiation of any new medications that might reasonably affect the immune response or viral load within 4 weeks prior to screening
•Tetanus booster immunization within 2 months of screening, or a history of anaphylaxis or severe local reaction to the tetanus vaccine
•History of autoimmune disease at risk for recurrence
•Current malignancy, except Stage A or B cervical carcinoma or basal cell carcinoma
•Chronic viral hepatitis, due to Hepatitis B or Hepatitis C undergoing current treatment or Hepatitis B DNA greater than 25 pg/cc or Hepatitis C RNA greater than 20,000 IU/cc
•Currently undergoing treatment or prophylaxis for tuberculosis infection
•Chronic active infectious disease (other than HIV)

Related studies

NCT07209917 · Cervical Cancer, Human Papillomavirus (HPV) Infection, and more

NCT07044297 · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis

NCT07466836 · Human Immunodeficiency Virus (HIV)

NCT06598397 · Human Immunodeficiency Virus (HIV), Smoking Cessation

NCT07071623 · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)